scholarly journals Prognostic significance of immunohistochemical markers in Primary CNS lymphomas

2021 ◽  
Vol 6 (3) ◽  
pp. 160-165
Author(s):  
Indu Ramachandran Nair ◽  
Pooja Phalak ◽  
Bindhu Mangalath Rajamma ◽  
Aiswarya Pradeep ◽  
Ayyadurai Retnathankom ◽  
...  
Keyword(s):  
Survival Data ◽  
Prognostic Significance ◽  
Primary Cns Lymphoma ◽  
Proliferation Index ◽  
Cns Lymphoma ◽  
Ki 67 ◽  
Non Hodgkin Lymphoma ◽  
Immunohistochemical Markers ◽  
Cns Lymphomas ◽  
Ihc Markers

Primary CNS lymphoma (PCNSL) is a rare form of extra nodal Non-Hodgkin Lymphoma that is typically confined to the brain, spinal cord, lepto meninges and eyes. We studied the clinico pathological features of PCNSLs, immuno histochemical (IHC) markers expressed and the association of morphological features & IHC markers with clinical outcome. 30 cases of primary CNS lymphomas were studied. 25 cases were diffuse large B cell lymphomas, which were sub classified using Hans algorithm into GCB and non-GCB. The IHC markers done were CD20, CD3, BCL2, BCL6, MUM-1, CD10 and c-myc. Mean proliferation index Ki was 80%. Follow up and survival data was collected and the association of each IHC marker and subtype with prognosis was assessed. PCNSL forms around 2% of all lymphomas as well as primary CNS tumours. Non GCB type is more common (72%). Mean overall survival was 9.7 months. Ki-67 index of 80% or more is the only independent variable of prognostic significance. None of the other IHC markers or sub typing had any influence on the outcome.

scholarly journals Del(6)(q22) and BCL6 Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course

2008 ◽  
Vol 26 (29) ◽  
pp. 4814-4819 ◽  
Author(s):  
Francois M. Cady ◽  
Brian Patrick O'Neill ◽  
Mark E. Law ◽  
Paul A. Decker ◽  
David M. Kurtz ◽  
...  
Keyword(s):  
Survival Data ◽  
Proportional Hazards ◽  
Deep Structure ◽  
Primary Cns Lymphoma ◽  
B Cell Lymphoma ◽  
Aggressive Lymphoma ◽  
Cns Lymphoma ◽  
High Dose ◽  
Putative Tumor Suppressor Gene ◽  
Thin Sections

Purpose Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clinically validated biologic markers that can predict natural history to tailor treatment according to risk are lacking. Several genetic changes including BCL6 rearrangements and deletion of 6q22, containing the putative tumor suppressor gene PTPRK, are potential risk predictors. Herein we determined the prevalence and survival impact of del(6)(q22) and BCL6, immunoglobulin heavy chain (IGH), and MYC gene rearrangements in a large PCNSL cohort treated in a single center. Patients and Methods Interphase fluorescence in situ hybridization was performed using two-color probes for BCL6, MYC, IGH-BCL6, and del(6)(q22) on thin sections of 75 paraffin-embedded samples from 75 HIV-negative, immunocompetent patients newly diagnosed with PCNSL. Survival data were analyzed using Kaplan-Meier survival curves, log-rank tests, and proportional hazards regression adjusting for age, deep structure involvement, and high-dose methotrexate (HDMTX) treatment. Results The prevalence of del(6)(q22) and BCL6, IGH, and MYC translocations was 45%,17%, 13%, and 3%, respectively. The presence of del(6)(q22) and/or a BCL6 translocation was associated with inferior overall survival (OS; P = .0097). The presence of either del(6)(q22) alone or a BCL6 translocation alone was also associated with inferior OS (P = .0087). Univariable results held after adjusting for age, deep structure involvement, and HDMTX. Conclusion Del (6)(q22) and BCL6 rearrangements are common in PCNSL and predict for decreased OS independent of deep structure involvement and HDMTX. Unlike systemic diffuse large B-cell lymphoma, del(6)(q22) is common and IGH translocations are infrequent and usually involve BCL6 rather than BCL2, suggesting a distinct pathogenesis.

scholarly journals Primary CNS Lymphoma

2017 ◽  
Vol 35 (21) ◽  
pp. 2410-2418 ◽  
Author(s):  
Christian Grommes ◽  
Lisa M. DeAngelis
Keyword(s):  
Primary Cns Lymphoma ◽  
Phase Iii ◽  
Cns Lymphoma ◽  
High Dose ◽  
First Line ◽  
Phase Iii Trial ◽  
Non Hodgkin Lymphoma ◽  
Systemic Spread ◽  
Line Setting ◽  
The Brain

Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic spread. The prognosis of patients with PCNSL has improved during the last decades with the introduction of high-dose methotrexate. However, despite recent progress, results after treatment are durable in half of patients, and therapy can be associated with late neurotoxicity. PCNSL is an uncommon tumor, and only four randomized trials and one phase III trial have been completed so far, all in the first-line setting. To our knowledge, no randomized trial has been conducted for recurrent/refractory disease, leaving many questions unanswered about optimal first-line and salvage treatments. This review will give an overview of the presentation, evaluation, and treatment of immunocompetent patients with PCNSL.

The impact of Epstein-Barr virus status on primary CNS lymphoma survival.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13528-e13528
Author(s):  
Isabel P Prado ◽  
Frank Barbiero ◽  
Joachim M. Baehring ◽  
Kevin Becker ◽  
Zachary Corbin
Keyword(s):  
Overall Survival ◽  
Epstein Barr Virus ◽  
Primary Cns Lymphoma ◽  
Cns Lymphoma ◽  
Event Free Survival ◽  
Free Survival ◽  
Barr Virus ◽  
Immunohistochemical Markers ◽  
Epstein Barr ◽  
The Impact

e13528 Background: Primary CNS lymphoma (PCNSL) incidence is increasing among the elderly and immunocompromised. Especially for these vulnerable populations, a deeper understanding of the prognostic value of tumor biomarkers is necessary to recommend more targeted therapies. Our primary objective is to evaluate the predictive strength of immunohistochemical markers on PCNSL overall survival. Secondary objectives include estimating the impact of these biomarkers on event-free survival. Methods: We retrospectively analyzed PCNSL patients treated at Yale between 2000 and 2018. The primary endpoint is overall survival. Event-free survival, measured by time to relapse or death, is the secondary endpoint. Kaplan-Meier survival curves with log-log confidence intervals were used to estimate survival outcomes. Cox proportional hazards regression models were used to evaluate the statistical significance (at alpha = 0.05) of immunohistochemical markers. Results: One hundred ten subjects were analyzed. Not all biomarkers were available for every subject. The median age of the cohort is 64 years. Sixty-three patients died, and seventy-six experienced an event (progression or death). Surviving patients had a median follow-up of 4.36 years. The median overall survival is 2.63 years (95% confidence interval (CI): 1.13 to 5.98 years). Epstein-Barr virus (EBV) status by immunohistochemistry significantly impacted overall survival. Adjusting for age and immunocompromised status, EBV-positive patients had a higher risk of death than EBV-negative patients (n = 13, hazard ratio (HR) = 33.75, 95% CI: 1.61-708.68). Other significant biomarkers include the GFAP and S100 proteins. The median event-free survival is 1.13 years (95% CI: 0.66 to 2.12 years), and EBV-positive patients had an increased risk of event (HR = 38.23, 95% CI: 2.32-630.88). CD10, BCL2, BCL6, and MUM1 were not significant to predict either survival outcome. Conclusions: We describe a large cohort of PCNSL patients treated at a single institution with comparable survival outcomes to similar research yet conflicting evidence of biomarker significance. Multi-institutional studies may further clarify the prognostic role of immunohistochemistry for improved PCNSL patient survival.

Primary Cutaneous Small/Medium CD4+ T-Cell Lymphomas: A Heterogeneous Group of Tumors With Different Clinicopathologic Features and Outcome

2008 ◽  
Vol 26 (20) ◽  
pp. 3364-3371 ◽  
Author(s):  
Adriana Garcia-Herrera ◽  
Luis Colomo ◽  
Mireia Camós ◽  
Joaquín Carreras ◽  
Olga Balague ◽  
...  
Keyword(s):  
T Cell ◽  
Prognostic Significance ◽  
Heterogeneous Group ◽  
Automated Image Analysis ◽  
Proliferation Index ◽  
Image Analysis System ◽  
Ki 67 ◽  
Cutaneous Lymphomas ◽  
Analysis System

Purpose To define the clinical and pathologic characteristics of primary cutaneous small/medium CD4+ T-cell lymphoma (PCSM-TCL) and identify parameters of prognostic significance. Patients and Methods We have investigated 24 patients with primary cutaneous lymphomas composed of small/medium mature T-cells with a βF1, CD3, CD4+ and/or noncytotoxic, CD8– and CD30– phenotype. The proliferation index and CD8+ infiltrating cells were quantified with an automated image analysis system. Results Sixteen patients presenting with solitary or localized plaques or small nodules (< 3 cm) had an indolent course. Only three patients experienced repeated cutaneous relapses, and none of them died as a result of the disease after 1 to 168 months (median, 17 months) of follow-up. The tumors had a low proliferation (median Ki-67, 9% ± 5%) and an intense infiltrate of reactive CD8+ (median, 20% ± 11.7%). Five patients presenting with rapidly evolving large tumors or nodules (≥ 5 cm) had an aggressive disease and died with extracutaneous dissemination 18 to 36 months after diagnosis (median, 23 months). These tumors had a significantly higher proliferation (median Ki-67, 22% ± 11.3%; P < .05) and lower number of infiltrating CD8+ (median, 1% ± 3%; P < .05) than the previous group. A third group of three patients had a peculiar clinical presentation with multifocal relapsing lesions without extracutaneous dissemination after a long period of follow-up ranging from 41 to 92 months. Histologically, these cases had an intense infiltrate of eosinophils. Conclusion PCSM-TCL is a heterogeneous group of tumors with differentiated clinical and pathological characteristics with impact in the outcome of the patients.

Ki-67 (clone MIB-1) proliferation index in recurrent glial neoplasms: no prognostic significance

1998 ◽  
Vol 50 (6) ◽  
pp. 579-585 ◽  
Author(s):  
N.Scott Litofsky ◽  
T.-Christian H. Mix ◽  
Stephen P. Baker ◽  
Lawrence D. Recht ◽  
Thomas W. Smith
Keyword(s):  
Prognostic Significance ◽  
Proliferation Index ◽  
Ki 67 ◽  
Mib 1

scholarly journals POSSIBILITIES OF THERAPY OF PAIN SYNDROME IN ENDOMETRIOSIS

2021 ◽  
pp. 23-29
Author(s):  
Yu. A. DUBOSSARSKAYA ◽  
Z. M. DUBOSSARSKAYA ◽  
L. P. GREK
Keyword(s):  
Pelvic Pain ◽  
Depressive Disorders ◽  
Pain Syndrome ◽  
Underlying Disease ◽  
Proliferation Index ◽  
Ki 67 ◽  
Immunohistochemical Markers ◽  
Group I ◽  
Choice Of Treatment ◽  
Reactive Anxiety

Therapeutic tactics of endometriosis are aimed primarily at overcoming the pain syndrome, the absence of recurrence of the underlying disease, maintaining fertility and improving the psycho-emotional state of women. The objective to develop, pathogenetically substantiate treatment and rehabilitation measures taking into account pathogenetic preconditions in women with endometriosis in combination with pain. Materials and methods 85 patients with genital endometriosis with severe pelvic pain (VAS 7-10 points) (n = 44) - group I and moderate (VAS 4-6 points) (n = 41) - group II. The mean age of women in clinical trials I and II of the study was 37.71 ± 0.93 and 41.05 ± 1.08 (M ± m) years, respectively. The choice of treatment tactics was determined on the basis of immunohistochemical markers: estrogen receptors (ER), progesterone (PGR), proliferation index (Ki-67), vasculoendothelial growth factor (VEGF), cyclooxygenase-2 (COX-2) in eutopic acid., psychoemotional characteristics and intensity of pelvic pain. Rеsultes of treatment in the examined patients a significant (p <0.05) reduction of pelvic pain was determined, both in the short and long term. After 6 months, the level of personal anxiety decreased - by - 38.62%, after 12 months. – at - 48.15% (p <0.05). The rate of decrease in the level of depressive disorders on the Hamilton scale of all studied women was: - 32.2% after 6 months and -42.15% after 12 months (p <0.05). Conclusion our approach to treating endometriosis helped to overcome pain in 83.53% of women, improve psycho-emotional and general condition, normalize sleep - was determined in 88.3% of women, reduce reactive anxiety and depressive disorders in 84.7% of patients, indicates the effectiveness proposed therapy.

Sign in / Sign up

Export Citation Format

Share Document